Investor Overview

Investors

Additional Resources

Shareholder Tools

Print Page
Email Page
Email Alerts
RSS Feeds
Financial Tear Sheet

NASDAQ: XBIT0.24.19Data provided by Nasdaq.
Minimum 15 minutes delayed.

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Recent News

Date	Title
09/21/17	XBiotech to Present at Cantor Fitzgerald’s Global Healthcare Conference
09/20/17	XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
09/07/17	XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

Upcoming Events

Date

Title

09/27/17
2:50 p.m. ET

XBiotech Inc at the Cantor Fitzgerald’s Global Healthcare Conference
Location	InterContinental New York Barclay Hotel